Iron
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Iron
- Iron: From Iron Deficiency Anemia to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia
Iron: From Iron Deficiency Anemia to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anemia
One-Sentence Summary
Iron is an established treatment for iron deficiency anemia and related nutritional anemias. The TxGNN model predicts it may be effective for vitamin B12- and folate-independent constitutional megaloblastic anemia, but 0 clinical trials and 0 publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Iron deficiency anemia (also folic acid deficiency anemia, anemia of prematurity, hypochromic anemia, microcytic anemia, deficiency anemia) |
| Predicted New Indication | Vitamin B12- and folate-independent constitutional megaloblastic anemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, iron is an essential mineral that supports haemoglobin synthesis. Its efficacy in iron deficiency anemia is well established. The original indications are all anemias, and the predicted indication is also an anemia, which likely explains the model's output.
The data compiled for this report argues against a true mechanistic link. Megaloblastic anemia is driven by impaired DNA synthesis. This particular form is defined as independent of vitamin B12 and folate, and it is not caused by iron deficiency. The high score most likely reflects the closeness of the anemia nodes in the knowledge graph rather than a real pharmacological relationship. No trials or publications were found to test the prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN14035P | Ferinject Solution for Injection 50mg/ml | Injection, solution |
| SIN14981P | Maltofer Film-Coated Tablets 100mg | Tablet, film coated |
| SIN16513P | Avofer Injection 100mg/5ml | Injection |
| SIN05699P | Maltofer Drops 50 mg/ml | Solution |
| SIN14727P | Velphoro® Chewable Tablets 500mg | Tablet, chewable |
A sixth authorization, SIN14341P (Nutritrace Concentrate for solution for infusion), is also valid. All 6 are valid single-ingredient registrations, and none is cancelled. Approved indication text was not available for these products. The list covers oral and injectable routes, and some products (for example Velphoro and Nutritrace) are likely to serve purposes other than treating iron deficiency anemia.
Safety Considerations
- Conditions flagged in the knowledge graph (not label text): Iron has recorded contraindication links with peptic ulcer disease, hereditary hemochromatosis, hemosiderosis, iron metabolism disease, Wilson disease, ulcerative colitis, inflammatory bowel disease, hemolytic anemia and gastroenteritis.
- Drug Interactions: 79 interactions were identified.
- Major: dolutegravir and bictegravir.
- Moderate: tetracycline and doxycycline, ciprofloxacin and delafloxacin, omeprazole and rabeprazole, alendronic acid, risedronic acid and ibandronate, levodopa, cefdinir, chloramphenicol, deferiprone, magnesium oxide, sodium citrate, pancrelipase and baloxavir marboxil.
- Minor: cimetidine.
- Most of these involve reduced absorption through chelation or altered gastric acidity. Dose separation or alternative therapy may be needed.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature (L5). Megaloblastic anemia that is independent of B12 and folate is not driven by iron deficiency, so a real mechanism is implausible. Iron is already marketed in Singapore for its established anemia uses, but nothing here supports a new indication.
To proceed, the following is needed:
- A plausible mechanism, together with detailed mechanism of action data for iron
- Any clinical or case-level evidence of iron benefit in this specific form of megaloblastic anemia
- Package insert warnings and contraindications from the HSA labels
Other predicted indications in the same analysis:
- Plummer-Vinson syndrome (L4) has substantial literature, mostly reviews and case reports. It is essentially an on-label use of iron for iron deficiency anemia, so it is not a true repurposing candidate.
- Injury and perinatal disease reached L1 through Phase 3 and Phase 4 trials. These trials largely address anemia in trauma, hip fracture or pregnancy, or test multi-nutrient supplements, so they overlap with the original anemia indication. They would be better framed as extensions of anemia treatment than as new disease indications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.